7 recruiting, 2 not yet recruiting. 5 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 2 | 5 | Recruiting 5 |
| Phase 3 | 1 | Recruiting 1 |
Follow Relapsed Refractory Multiple Myeloma (RRMM): new trials by email Literature Review of Relapsed Refractory Multiple Myeloma (RRMM) trials Research Report on Relapsed Refractory Multiple Myeloma (RRMM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM CM336 (BCMA/CD3 bispecific antibody) - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-06-01 | 2026-02-12 |
| A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 34 | 2026-03-31 | 2026-09-18 |
| A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma Linvoseltamab, REGN17372+Linvoseltamab - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 150 | 2026-03-26 | 2026-09-11 |
| Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma Talquetamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Massachusetts General Hospital | 25 | 2025-12-19 | 2026-04-13 |
| Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy Letermovir - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 2 | Recruiting | Seoul National University Hospital | 40 | 2025-09-11 | 2025-12-03 |
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma Linvoseltamab, Elotuzumab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 410 | 2023-09-18 | 2026-10-07 |
Multiple Myeloma (9) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Blood Protein Disorders (9) · Cardiovascular Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Paraproteinemias (9) · Vascular Diseases (9) · Neoplasms, Plasma Cell (8) · Disease Attributes (1)
Dexamethasone (3) · pomalidomide (2) · Calcium Dobesilate (1) · belantamab mafodotin (1) · elotuzumab (1) · isatuximab (1) · letermovir (1) · talquetamab (1)
Massachusetts General Hospital (2) · Regeneron Pharmaceuticals (2) · Canadian Myeloma Research Group (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · Seoul National University Hospital (1) · YOUNGIL KOH (1)
United States (4) · South Korea (3) · Australia (2) · Canada (2) · Singapore (2) · Belgium (1) · Brazil (1) · Chile (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Andrew J. Yee, MD (1) · Christine Ye, MD (1) · Noopur Raje, MD (1) · Suzanne Trudel, MD (1)
2025 (1)